Published online Sep 18, 2024. doi: 10.13105/wjma.v12.i3.95631
Revised: August 24, 2024
Accepted: September 4, 2024
Published online: September 18, 2024
Processing time: 151 Days and 14.1 Hours
Blastocystis hominis (B. hominis), an anaerobic unicellular protist parasite, is known for its diverse clinical manifestations upon infecting the human gastrointestinal tract. Although globally distributed, it is particularly prevalent in developing nations. Examining the symptoms and treatment outcomes of B. hominis infection in low-resource settings holds immense significance, providing healthcare practitioners with valuable insights to enhance patient care.
To synthesize existing evidence on the symptomatology and treatment outcomes of B. hominis infection in low-resource settings.
Following the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines, a systematic review was conducted. The search spanned electronic databases including PubMed, Scopus, and Google Scholar. After a comprehensive screening process, a thorough examination of the papers, adhering to inclusion and exclusion criteria, and data extraction from eligible studies was conducted. The findings underwent summarization through simple descriptive analysis.
The search yielded 1200 papers, with 17 meeting inclusion criteria. Chronic diarrhea due to B. hominis infection was reported in only two studies, while abdominal pain, diarrhea, flatulence, constipation, and nausea/vomiting emerged as the most commonly documented symptoms. Recovery rates after one week of treatment ranged from 71.8% to 100%, and after two weeks, from 60% to 100%.
In low-resource settings, chronic diarrhea resulting from B. hominis infection is infrequent. Common symptoms include abdominal pain, diarrhea, flatulence, constipation, and nausea/vomiting. Post-treatment, clinical outcomes are notably favorable, supporting the recommendation for treatment. Metronidazole is advocated as the first-line agent, with consideration for switching to a second-line option in cases of treatment failure or poor response.
Core Tip: This systematic review highlights the symptomatology and treatment outcomes of Blastocystis hominis (B. hominis) infection in low-resource settings. Notably, chronic diarrhea due to B. hominis is rare in these contexts. Abdominal pain, diarrhea, flatulence, constipation, and nausea/vomiting are the predominant symptoms reported. Post-treatment recovery rates are promising, ranging from 60% to 100% after two weeks of treatment. Metronidazole is recommended as the initial treatment, with consideration for alternative options if needed. These findings provide valuable insights for healthcare practitioners managing B. hominis infections in resource-limited settings.